We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Biomarkers Provide Diagnostic Tool for AD

By LabMedica International staff writers
Posted on 09 Aug 2017
Print article
Image: The CytoViva hyperspectral imaging system (Photo courtesy of CytoViva).
Image: The CytoViva hyperspectral imaging system (Photo courtesy of CytoViva).
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder that results in the gradual deterioration of specific brain regions that hinders the person’s ability to think, recall memories, learn, and perform daily tasks.

Currently, AD is diagnosed using the “evaluate and eliminate” approach. With this strategy, patient history, physical exams, laboratory tests, imaging scans, and neurophysiological assessments are examined by doctors as a means to diagnose AD and determine its progression.

Scientists at Ohio State University (Columbus, OH, USA) and their colleagues analyzed 34 cerebrospinal fluid (CSF) samples from 24 patients with AD and from 10 healthy individuals serving as controls. They analyzed 30 serum samples from 22 patients with AD and from eight healthy individuals serving as controls. The processed CSF samples were combined with rabbit-derived primary antibodies anti-Aβ(1–42) antibody) and anti-tau) and goat-derived anti-rabbit secondary antibody in immunofluorescence assays.

A CSF sample of 10 μL was dried on a slide glass surface for atomic force microscopy (AFM) nanomechanics characterization. Hyperspectral microscope imaging was used for particle visualization and analysis and using the system, images of micro-/nanoscale structures and micro-/nanoparticles were captured. Coated with gold and anti-Aβ(1–42) antibody, AFM tips were functionalized to specifically detect the Aβ-embedded proteins inside human serum. Serum or anti-Aβ(1–42) antibody was used to coat the substrates, respectively.

The scientists showed that showed that nanoscale physical properties of protein aggregates from the cerebral spinal fluid and blood of patients are altered during AD pathogenesis and that these properties can be used as a new class of “physical biomarkers”. Using a computational algorithm, developed to integrate these biomarkers and cognitive assessments, they demonstrated an approach to impartially diagnose AD and predict its progression.

Mingjun Zhang, PhD, DSc, a professor of Biomechanical Engineering, and lead investigator of the study said, “With a tool like this you may predict how fast this disease will go, and currently we can't do that, we just know everyone is different. Looking at multiple indicators of the disease all at once increases the reliability of the diagnosis and prognosis.” The study was published on July 28, 2017, in the journal Science Advances.

Related Links:
Ohio State University

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
RFID Inlay
Minidose U8 RAIN

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.